PTEN loss is associated with resistance to cetuximab in patients with head and neck squamous cell carcinoma

INTRODUCTION: Cetuximab, a monoclonal antibody to the epidermal growth factor receptor (EGFR), extends survival in combination with standard therapy in head and neck squamous cell carcinoma (HNSCC). However, as effects are modest, and patients experience side effects, a biomarker to predict resistan...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oral Oncol
Main Authors: Eze, Nnamdi, Lee, Ju-Whei, Yang, Dong-Hua, Zhu, Fang, Neumeister, Veronique, Sandoval-Schaefer, Teresa, Mehra, Ranee, Ridge, John A., Forastiere, Arlene, Chung, Christine H., Burtness, Barbara
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6855599/
https://ncbi.nlm.nih.gov/pubmed/30926065
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.oraloncology.2019.02.026
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados